Back to Agenda
Session 4: Digital Health & Personalized Medicine
Session Chair(s)
Lakshman Ramamurthy, PhD
Head of Global Regulatory, Precision Medicine and Digital Health
GlaxoSmithKline, United States
Megan Doyle, JD, MPH
Global Policy Lead, Digital Health, Diagnostics, Oncology
Amgen, United States
Recent advances in mobile technologies and digital health have enabled sensor-based technologies for objective, quantitative, remote, and continuous monitoring of health and disease. These devices not only provide the ability to measure much more detailed disease phenotypes than traditional clinical examination, but also provide the ability to follow patients longitudinally with much higher frequency than is possible through other means.
Learning Objective : At the conclusion of this session, participants should be able to:
- Discuss current challenges around the pathways and level of evidence to enable qualification of a novel digital measure
- Identify flexibilities across industry on the technologies, study designs, and data analytic methodologies
- Discuss methods for advancing the development of these technologies and learn from recent successes
Speaker(s)
Speaker
John Bertrand
Digital Diagnostics, United States
CEO
Speaker
Rob Berlin, JD, MPH
GlaxoSmithKline, United States
Head, US Regulatory Policy
Speaker
Noah Zimmerman, PhD
Tempus, Inc., United States
Vice President, Translational Science
Speaker
Bakul Patel, MBA, MS
Google Health, United States
Senior Director, Global Digital Health Strategy and Regulatory
Have an account?